|
|
Effective December 19, 2018 Strongbridge sold the United States and Canadian rights to Macrilen™ (macimorelin) under the License and Assignment Agreement to Novo
2019
On January 16, 2019, the Company announced that the EMA granted marketing authorization
March 12, 2019 The Special Committee has approved the engagement by the Company of Torreya
September 24, 2019 : KE 3,325,000 Common Shares zu 1,5$ + 3,325,000 Warrants zu 1,65$ gezeichnet u.A. von Empery Asset Management, LP ( Event-Driven-Strategie Hedgefond)
16,632,410 Common Shares auf 19,957,410 Common Shares
2020
March 10, 2020 Ablauf Warrants March 2015 offering - Series A 28,144 1.07$
March 20, 2020 Die neuen Warrants können ausgeübt werden (3,325,000 Warrants zu 1,65)
May 1, 2020 Ablauf Warrants November 2016 offering 945,000 4.70$
Jun 2020 Max. ende Kohle ohne die neue KE bei 2,6 Mio Verlust pro Q
By July 2020 Date of completion: Study AEZS-130-P01 Teil 1 PIP
Okt-Nov 2020 14 Mio$ cash : Sollte im Q4 2020 verbraucht sein
December 13, 2020 Ablauf Warrants December 2015 offering 2,331,000 7.10$
2021
Apr-Mai Ende Kohle nach einer Ausübung der 1,65$ Warrants (neue KE)
2022
July 2022 Date of completion: Study AEZS-130-P02 Teil 2 PIP ( Upon approval by the U.S. Food and Drug Administration (“FDA”) of a pediatric indication for Macrilen™ (macimorelin), Aeterna Zentaris will receive a one-time milestone payment of US$5,000,000 from Strongbridge. )
2023
2024
September 20, 2024 Ablauf Warrants der neuen KE
Zur Fundamentalen Transaktion (BO)
The Corporation shall not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity assumes in writing all of the obligations of the Corporation under this Warrant in accordance with the provisions of this Section 2(f) pursuant to written agreements in form and substance satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding number of shares of share capital equivalent to the Common Shares acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of share capital (but taking into account the relative value of the Common Shares pursuant to such Fundamental Transaction and the value of such shares of share capital, such adjustments to the number of shares of share capital and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction)
Black Scholes Valuation.
Notwithstanding the foregoing and the provisions of Section 2(f) above, at the request of the Holder delivered at any time commencing on the date of the public disclosure of any Fundamental Transaction through the date that is ninety (90) days after the public disclosure of the consummation of such Fundamental Transaction, the Corporation or the Successor Entity (as the case may be) shall purchase this Warrant from the Holder within five (5) Business Days of such request by paying to the Holder cash in an amount equal to the Black Scholes Value.
Bedeutet doch das die Warrants bei einem BO nach dem Black Scholes Value mit dem dann herschenden Preis direkt vor der Transaktion berechnet wird. Also nach der Ankündigung einer Fundamentalen Transaktion.
Number of equivalent shares | Market value per share price | Weighted average exercise price | Risk-free annual interest rate | Expected volatility | Expected life (years) | Expected dividend yield | ||||||||||||||||||||||
($) | ($) | (a) | (b) | (c) | (d) | |||||||||||||||||||||||
March 2015 Series A Warrants (e) | 28,144 | 2.95 | 1.07 | 1.91 | % | 100.09 | % | 0.70 | 0.00 | % | ||||||||||||||||||
December 2015 Warrants | 2,331,000 | 2.95 | 7.10 | 1.83 | % | 80.62 | % | 1.46 | 0.00 | % | ||||||||||||||||||
November 2016 Warrants (f) | 945,000 | 2.95 | 4.70 | 1.91 | % | 92.73 | % | 0.84 | 0.00 | % |
http://app.quotemedia.com/data/...dateFiled=2019-08-13&CK=1113423
Berechnen mit
https://www.mystockoptions.com/...;v=92.73%25&calculate=Calculate
Ich bekomme bei 12$ Kurs für die 945,000 Nov Warrants einen Preis von 7,735$ je Aktie
Sind ca. 7,3 Mio$ bei einem BO an die Warranthalter zu zahlen
Die Dez 15 Warrants schlagen mit ca 15Mio$ zu Buche
Bei einem Aktienkursurs zu 15$ ergab sich schon ein Preis von 10 und 21Mio$ als Ablöse der Warrants.
Ein Kurs um 15$ entsprach vor der neuen KE einer MK vo 250Mio$
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
25 | 17.117 | Aeterna nach dem Split | Heron | Hbit | 25.11.23 10:08 | |
9 | 13.769 | AEZS vs. KERX | Gropius | paioneer | 03.09.22 18:22 | |
19 | Wie geht's jetzt weiter mit Aeterna Zentaris? | Ebi52 | Bullish_Hope | 03.08.22 00:11 | ||
21 | 7.680 | Aeterna Zentaris Inc. | Heron | Heron | 30.09.21 23:37 | |
2 | 62 | AEterna Zentaris (AEZS)- Reboundkandidat?? | Vollzeittrader | marroni | 25.04.21 13:13 |